JAK2 and erythroleukemia: To further support the hypothesis that CM363 was able to inhibit constitutive pYStat5 in leukemia cells, we assessed the effects of CM363 on HEL, a human erythroleukemia cell line harboring constitutive activation of Jak2/Stat5 signaling pathway [24].